engleski

Comparison of measured and calculated LDL-C in HIV-positive patients

Background: Dyslipidemia has been described in treated HIV-patients as a side effect of antiretroviral therapy and therefore lipid status is an essential part of monitoring HIV- positive patients. In the present study we compared measured with calculated low density lipoprotein cholesterol (LDL-C) (Friedewald’s formula and a recently new Anandaraja’s formula) in HIV-positive patients. Materials and methods: Determination of triglycerides and cholesterol (Thermo Fisher Scientific, USA), direct LDL-C (D-LDL-C) and HDL-C (Dijagnostika d.o.o., Croatia) was done on Beckman Coulter AU400 analyzer in sera of HIV-positive patients (N = 98). Calculation of LDL-C with Friedewald’s and Anandaraja’s formulas was performed. Measured D-LDL-C was compared with calculated LDL-C. Statistical analysis was done with MedCalc software (version 12.7.0). Results: Mean and standard deviation for LDL-C concentrations were as follows: 2.53 ± 0.79 mmol/L (D-LDL-C), 3.15 ± 1.13 mmol/L calculated by Friedewald’s formula (F-LDL-C) and 3.46 ± 1.14 mmol/L calculated by Anandaraja’s formula (A-LDL-C). Passing-Bablok regression analysis showed a constant difference between D-LDL-C and F-LDL-C, but not between D-LDL-C and A-LDL- C and a proportional difference for measured D- LDL-C and both equations (D-LDL-C vs. F-LDL-C: y=-0.259 + 1.353 x ; D-LDL-C vs. A-LDL-C: y = -0.425 + 1.500 x). Bland-Altman plot showed a mean difference between methods: D-LDL-C vs. F-LDL-C -0.62 mmol/L (95% CI: -1.50 to 0.27) and D-LDL-C vs. A-LDL-C -0.93 mmol/L (95% CI: -2.07 to 0.21). Conclusion: According to our results, measured and calculated LDL-C should not be used interchangeably in HIV-postive patients. Friedewald’s and Anandaraja’s equation generally overestimate LDL-C in HIV patients.

low density lipoprotein cholesterol ; Friedewald’s formula ; Anandaraja’s formula

nije evidentirano